CAR-T therapy: what happens years later? new study tracks Long-Term risks
Knowledge-focused
ENROLLING_BY_INVITATION
This study follows about 178 people who previously received an experimental AvenCell CAR-T cell therapy for blood cancers or prostate cancer. Researchers will monitor participants for years to check for delayed side effects, such as new cancers, nerve disorders, or severe infecti…
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC